Novacyt « Terug naar discussie overzicht

Novacyt de volgende biotech raket!

64.987 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ... 3246 3247 3248 3249 3250 » | Laatste
BP
0
Ik wel, denk langzaam verder omhoog.
Grote verkoper is klaar en moest helaas verkopen.
Nu dus herstel
Show_Me_The_Money
0
Ik zie dat deze, voor wat het waard is, hier nog niet is geplaatst:

NOVACYT PARTNERS WITH APPLIED MICROARRAYS
IN ASSAY DESIGN

US partnership to facilitate the design and optimisation for
customised microarray assays

Paris, France and Camberley, UK – 13 September 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has partnered with Applied Microarrays, Inc. (AMI), a company that specialises in providing customised microarrays and manufacturing point-of-care (POC) and high throughput DNA and protein arrays, to offer comprehensive single nucleotide polymorphism (SNP) assay development.

Primerdesign will play an integral part in designing probes for AMI and their customers. The microarray based molecular diagnostic tests developed under this partnership will play a crucial role in the early diagnosis, as well as improve patient management and outcome. Primerdesign has thirteen years’ experience in molecular assay design and this partnership highlights the division’s pivotal role in assay development as it grows its relationships with leading diagnostic companies.

Working together, Primerdesign and AMI can provide a full suite of assay development services from probe designs, through to assay optimisation, regulatory and ultimately high volume manufacturing of SNP microarrays for use in POC as well as laboratory-based settings.

Alastair Malcolm, President & CEO of AMI, commented:
“Novacyt is an expert in molecular diagnostic assay design and development and I am pleased to enter this strategic partnership to develop customised microarray based diagnostic tests. Through working with Primerdesign, we have been impressed with their assay development expertise and ability to deliver a high quality service in a timely manner. I am confident that our partnership will help us to deliver multiplexed probe based diagnostic and detection with better diagnosis and improved patient outcomes.”

Graham Mullis, Group CEO of Novacyt, added:
“I am delighted that we are entering into a partnership with AMI. This partnership significantly expands our offering and geographic reach as we continue to expand our molecular products business.
“I am also pleased to see continued progress in our business-to-business opportunities converting into commercial partnerships. We are increasingly becoming the partner of choice for molecular diagnostic companies and I look forward to updating shareholders with further partnerships like this.”

Financial terms of the agreement have not been disclosed.
LB91
1
Wat een drama aandeel, ben benieuwd of Ponzi ons binnenkort nog wat meer kan vertellen.
Show_Me_The_Money
0
Paris, France and Camberley, UK – 26 September 2018 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostic products, today announces unaudited financial results for the six months ended 30 June 2018.
Unaudited revenues were broadly flat at €7.0m following a strong performance by the Primerdesign and Lab21 Products divisions, offset by lower sales from NOVAprep®. Group gross margin increased to 64% (61% H1 2017) and the EBITDA loss was €0.5m. Excluding NOVAprep®, the Group achieved EBITDA breakeven.

Financial highlights
• Consolidated unaudited Group revenue of €7.0m, marginal increase compared to H1 2017
o Primerdesign revenue increased 15% (18% CER) to €3m
o Lab21 revenue increased 3% (6% CER) to €3.4m
o NOVAprep® revenue of €0.6m versus €1.1m in H1 2017
• Group revenue increased 1% at CER compared with H1 2017 as a result of a previously announced decision to re-optimise the NOVAprep® product, exacerbated by supply issues
• Excluding the impact of NOVAprep®, Group revenue increased 8% (11% at CER)
• Gross profit increased from €4.3m to €4.5m representing a three-percentage point increase from 61% to 64%
• EBITDA loss of €0.5m in H1 2018 was broadly similar to the same period in 2017 as a result of higher gross profit offset by NOVAprep® losses
• Excluding the impact of NOVAprep® EBITDA was at break-even for the first half
• Novacyt had €2.1m in cash and cash equivalents at the end of 30 June 2018

Het volledige bericht:

novacyt.com/wp-content/uploads/2018/0...

Als ik het goed zie 2 miljoen verlies in een half jaar en nog 2 miljoen in kas.
Reken maar uit.
Hopelijk komt er geen financiering a la Esperite of Visiomed uit de hoge hoed bij dit aandeel want dan gaat het ver naar beneden.
DeZwarteRidder
0
quote:

Show_Me_The_Money schreef op 26 september 2018 09:23:


Paris, France and Camberley, UK – 26 September 2018 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostic products, today announces unaudited financial results for the six months ended 30 June 2018.
Unaudited revenues were broadly flat at €7.0m following a strong performance by the Primerdesign and Lab21 Products divisions, offset by lower sales from NOVAprep®. Group gross margin increased to 64% (61% H1 2017) and the EBITDA loss was €0.5m. Excluding NOVAprep®, the Group achieved EBITDA breakeven.

Financial highlights
• Consolidated unaudited Group revenue of €7.0m, marginal increase compared to H1 2017
o Primerdesign revenue increased 15% (18% CER) to €3m
o Lab21 revenue increased 3% (6% CER) to €3.4m
o NOVAprep® revenue of €0.6m versus €1.1m in H1 2017
• Group revenue increased 1% at CER compared with H1 2017 as a result of a previously announced decision to re-optimise the NOVAprep® product, exacerbated by supply issues
• Excluding the impact of NOVAprep®, Group revenue increased 8% (11% at CER)
• Gross profit increased from €4.3m to €4.5m representing a three-percentage point increase from 61% to 64%
• EBITDA loss of €0.5m in H1 2018 was broadly similar to the same period in 2017 as a result of higher gross profit offset by NOVAprep® losses
• Excluding the impact of NOVAprep® EBITDA was at break-even for the first half
• Novacyt had €2.1m in cash and cash equivalents at the end of 30 June 2018

Het volledige bericht:

novacyt.com/wp-content/uploads/2018/0...

Als ik het goed zie 2 miljoen verlies in een half jaar en nog 2 miljoen in kas.
Reken maar uit.
Hopelijk komt er geen financiering a la Esperite of Visiomed uit de hoge hoed bij dit aandeel want dan gaat het nog veel verder naar beneden.


Dat laatste gaat 100% zeker gebeuren.
JR von P
0
De zwarteridder heeft gelijk gekregen, niet echt een voorspelling om nou trots op te zijn.. maar waar gaat dit naar toe ?
SJURVM
0
It seems to me as if management has some difficulties in selling the loss making Novaprep. Not good for the company's outlook. And money will be needed in H1 2019.
Show_Me_The_Money
0
Was hier al even niet geweest maar sinds mijn vorige post nog maar eens 25% van de koers af in 2 maanden tijd.

En de kas raakt leger en leger.
Binnenkort het bericht dat men "financiering" "krijgt" van het een of andere vage equity line fonds. Die gaan in ruil voor flinke korting hun winst maken door stukken z.s.m. te dumpen op de beurs boven de koers die zij betalen. Dan is het helemaal einde verhaal over de ruggen van de bestaande aandeelhouders.

Het zag er zo mooi en veelbelovend uit maar wat een treurig verhaal is dit toch geworden.

Capstone
0
De bodem lijkt in zicht. Hopelijk een dagje 100%. Als novaprep verkocht wordt zijn ze gewoon winstgevend.
wieweet
0
Zowel Capstone als Novacyt staan bij vele Ponzi aanhangers flink onder water...
Winst nemen is ook een vak..



vrgr
DeZwarteRidder
0
quote:

BP schreef op 26 oktober 2018 16:59:


Wordt tijd voor flinke rit omhoog, nieuws novaprep etc.

Natuurlijk zit BP ook in dit FLUT-aandeel........
SJURVM
0

Novacyt Signs $3.0M Diagnostics Supply Agreement with Genesis Diagnostics
November 27, 2018 02:00 AM Eastern Standard Time

PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News:

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has signed an exclusive supply agreement worth a minimum of $3 million with Genesis Diagnostics, a US-based full service diagnostic laboratory that offers clinical diagnostic testing, oral fluid drug testing and services focused on drug monitoring, substance abuse programmes, infectious disease, and personalised medicine.

Primerdesign will develop and supply 384 well plate molecular assay panels for respiratory, women’s health, sexually transmitted, wound and urinary tract infections for Genesis Diagnostics to use in its clinical service laboratory based in Langhorne, Pennsylvania.

Under the terms of the agreement, Primerdesign will be appointed the exclusive product manufacturer of the panel for a minimum of five years. The supply of product is expected to commence in early 2019 and Genesis Diagnostics will purchase minimum quantities of product to the value of $600,000 per year.
64.987 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 ... 3246 3247 3248 3249 3250 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 22 okt 2021 17:36
Koers 3,400
Verschil +0,435 (+14,67%)
Hoog 3,467
Laag 2,950
Volume 2.004.067
Volume gemiddeld 646.088
Volume gisteren 263.350

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront